For instance, anti-αLβ2 monoclonal antibodies previously used for immune-related diseases were discontinued due to inducing progressive multifocal leukoencephalopathy (PML), highlighting immunosuppression-related risks in integrin-targeted therapies (170). Here, AFM is linked to progressive multifocal leukoencephalopathy.